Clinical validation of a GPU-based Monte Carlo dose engine of a commercial treatment planning system for pencil beam scanning proton therapy.


Journal

Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB)
ISSN: 1724-191X
Titre abrégé: Phys Med
Pays: Italy
ID NLM: 9302888

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 11 03 2021
revised: 06 07 2021
accepted: 13 07 2021
pubmed: 27 7 2021
medline: 1 9 2021
entrez: 26 7 2021
Statut: ppublish

Résumé

To perform the validation of the GPU-based (Graphical Processing Unit based) proton Monte Carlo (MC) dose engine implemented in a commercial TPS (RayStation 10B) and to report final dose calculation times for clinical cases. 440 patients treated at the Proton Therapy Center of Trento, Italy, between 2018 and 2019 were selected for this study. 636 approved plans with 3361 beams computed with the clinically implemented CPU-MC dose engine (version 4.2 and 4.5), were used for the validation of the new algorithm. For each beam, the dose was recalculated using the new GPU-MC dose engine with the initial CPU computation settings and compared to the original CPU-MC dose. Beam dose difference distributions were studied to ensure that the two dose distributions were equal within the expected fluctuations of the MC statistical uncertainty (s) of each computation. Plan dose distributions were compared with respect to the dosimetric indices D The median over all mean beam dose differences between CPU- and GPU-MC was -0.01% and the median of the corresponding standard deviations was close to (√2s) both for simulations with an s of 0.5% and 1.0% per beam. This shows that the two dose distributions can be considered equal. All the DVH indices showed an average difference below 0.04%. About half of the plans were computed with 1.0% statistical uncertainty on a 2 mm dose calculation grid, for which the median computation time was 5.2 s. The median computational speed for all plans in the study was 8.4 million protons/second. A validation of a clinical MC algorithm running on GPU was performed on a large pool of patients treated with pencil beam scanning proton therapy. We demonstrated that the differences with the previous CPU-based MC were only due to the intrinsic statistical fluctuations of the MC method, which translated to insignificant differences on plan dose level. The significant increase in dose calculation speed is expected to facilitate new clinical workflows.

Identifiants

pubmed: 34311160
pii: S1120-1797(21)00256-8
doi: 10.1016/j.ejmp.2021.07.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

226-234

Informations de copyright

Copyright © 2021 Associazione Italiana di Fisica Medica. Published by Elsevier Ltd. All rights reserved.

Auteurs

Francesco Fracchiolla (F)

Protontherapy Department, Trento Hospital, Trento, Italy. Electronic address: francesco.fracchiolla@apss.tn.it.

Erik Engwall (E)

RaySearch Laboratories AB, Stockholm, Sweden.

Martin Janson (M)

RaySearch Laboratories AB, Stockholm, Sweden.

Fredrik Tamm (F)

RaySearch Laboratories AB, Stockholm, Sweden.

Stefano Lorentini (S)

Protontherapy Department, Trento Hospital, Trento, Italy.

Francesco Fellin (F)

Protontherapy Department, Trento Hospital, Trento, Italy.

Mattia Bertolini (M)

Protontherapy Department, Trento Hospital, Trento, Italy.

Carlo Algranati (C)

Protontherapy Department, Trento Hospital, Trento, Italy.

Roberto Righetto (R)

Protontherapy Department, Trento Hospital, Trento, Italy.

Paolo Farace (P)

Protontherapy Department, Trento Hospital, Trento, Italy.

Maurizio Amichetti (M)

Protontherapy Department, Trento Hospital, Trento, Italy.

Marco Schwarz (M)

Protontherapy Department, Trento Hospital, Trento, Italy; TIFPA - Trento Institute for Fundamental Physics and Applications, 14, Via Sommarive, 38123 Povo TN, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH